Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 23;13(3):213.
doi: 10.3390/antibiotics13030213.

Risk Factors Associated with Mortality in Acinetobacter baumannii Infections: Results of a Prospective Cohort Study in a Tertiary Public Hospital in Guayaquil, Ecuador

Affiliations

Risk Factors Associated with Mortality in Acinetobacter baumannii Infections: Results of a Prospective Cohort Study in a Tertiary Public Hospital in Guayaquil, Ecuador

Luz Abarca-Coloma et al. Antibiotics (Basel). .

Abstract

Antibiotic overuse and the resulting antimicrobial resistance pose significant global public health challenges, providing an avenue for opportunistic pathogens like Acinetobacter baumannii to thrive. This study will report the trends of Acinetobacter baumannii antimicrobial resistance patterns at the Hospital Teodoro Maldonado Carbo, Ecuador. An observational, analytical, longitudinal, and prospective study was conducted involving patients diagnosed with hospital-acquired infections. Antimicrobial susceptibility testing was performed, followed by molecular analysis of carbapenemase genes in Acinetobacter baumannii isolates. We included 180 patients aged from 16 to 93 years. The hospital mortality rate was 63/180 (35%). Invasive mechanical ventilation (IMV) was indicated in 91/180 patients (50.4%). The overall survival (OS) rate in patients on IMV was 49.5% (45/91), with a median survival of 65 days. The OS rate in patients not on IMV was 80.9% (72/89), with a median survival of 106 days (HR 2.094; 95% CI 1.174-3.737; p = 0.012). From multivariate analysis, we conclude that ventilator-associated pneumonia is the most related factor to OS.

Keywords: Acinetobacter baumannii; antimicrobial resistance; carbapenemase; colistin; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve of the survival probability over hospital stay (days) associated with invasive mechanical ventilation (IMV) in patients with Acinetobacter baumannii infection.

References

    1. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x. - DOI - PubMed
    1. Pattnaik D., Panda S.S., Singh N., Sahoo S., Mohapatra I., Jena J. Multidrug resistant, extensively drug resistant and pan drug resistant gram negative bacteria at a tertiary care centre in Bhubaneswar. Int. J. Commun. Med. Public Health. 2019;6:567–572. doi: 10.18203/2394-6040.ijcmph20190170. - DOI
    1. Cheng A., Chuang Y.C., Sun H.Y., Sheng W.H., Yang C.J., Liao C.H., Hsueh P.-R., Yang J.-L., Shen N.-J., Wang J.-T., et al. Excess Mortality Associated with Colistin-Tigecycline Compared with Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study*. Crit. Care Med. 2015;43:1194–1204. doi: 10.1097/CCM.0000000000000933. - DOI - PubMed
    1. World Health Organization Global Priority List of Antibiotics-Resistant Bacteria to Guide Research, Discovery, and Developement of New Antibiotics. 2017. [(accessed on 22 July 2021)]. Available online: https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of....
    1. Kempf M., Rolain J.M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options. Int. J. Antimicrob. Agents. 2012;39:105–114. doi: 10.1016/j.ijantimicag.2011.10.004. - DOI - PubMed

LinkOut - more resources